# Myocardial Protection in Patients With Post-acute Inflammatory Cardiac Involvement Due to COVID-19

Study · id `cardio:ct-nct05619653` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05619653](<https://clinicaltrials.gov/study/NCT05619653>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT05619653

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Heart failure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 279 participants.

## Technical summary

Registry record NCT05619653. Randomized; quadruple masking; primary purpose treatment. Start 2022-12-12 (actual); primary completion 2025-08-08 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 279 participants (enrolled count; ClinicalTrials.gov record NCT05619653, source copy `cardio:ctgov-nct05619653-2025-12-09`, retrieved 2026-10-31)
- Started: 2022-12-12 (actual) (ClinicalTrials.gov record NCT05619653, source copy `cardio:ctgov-nct05619653-2025-12-09`, retrieved 2026-10-31)
- Primary completion: 2025-08-08 (actual) (ClinicalTrials.gov record NCT05619653, source copy `cardio:ctgov-nct05619653-2025-12-09`, retrieved 2026-10-31)
- Completion: 2026-03-31 (anticipated) (ClinicalTrials.gov record NCT05619653, source copy `cardio:ctgov-nct05619653-2025-12-09`, retrieved 2026-10-31)
- Countries: Austria; Germany (ClinicalTrials.gov record NCT05619653, source copy `cardio:ctgov-nct05619653-2025-12-09`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05619653-2025-12-09`, retrieved 2026-10-31)

## The registry's words

- Brief title: Myocardial Protection in Patients With Post-acute Inflammatory Cardiac Involvement Due to COVID-19
- Acronym: MYOFLAME-19
- Condition: COVID-19 Associated Cardiac Involvement
- Condition: Remodeling, Left Ventricle
- Condition: Remodeling, Vascular
- Condition: Left Ventricular Dysfunction
- Condition: Exercise Intolerance
- Condition: Vascular Inflammation
- Condition: Microvascular Angina
- Condition: Long COVID
- Condition: Myocarditis, Pericarditis
- Intervention (Drug): Prednisolone
- Intervention (Drug): Losartan
- Lead sponsor: Valentina Puentmann
- Lead sponsor class: OTHER
- Collaborator: Bayer
- Collaborator class: INDUSTRY
- Collaborator: Alcedis GmbH
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Angina pectoris (`cardio:angina-pectoris`)
- Registry condition terms include this condition: Cardiomyopathy (heart muscle disease) (`cardio:cardiomyopathy`)
- Registry condition terms include this condition: Microvascular and vasospastic angina (`cardio:microvascular-and-vasospastic-angina`)
- Registry intervention name matches this record: Losartan (`cardio:losartan`)
- Registry lists this organization as a collaborator: Bayer (`cardio:bayer`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Losartan and prednisolone for post-COVID syndrome and cardiac inflammation: a randomized, double-blind, placebo-controlled trial (`cardio:pubmed-42533000`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 9dbc359f40eb0b1bdbb12467fbcccc060c01a056b9b430afb1cbfde2fdaf33ab
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
